Small

Zacks Small Cap Research – LGND: Initiating Coverage – A Prince Among Royalty – Go Health Pro

by
Zacks Small Cap Research – LGND: Initiating Coverage – A Prince Among Royalty – Go Health Pro

By John Vandermosten, CFA NASDAQ:LGND READ THE FULL LGND RESEARCH REPORT We are initiating coverage of Ligand Pharmaceuticals, Inc. (NASDAQ:LGND) and assign a valuation of $128 per share. This valuation is based on applying a multiple to our 2025 earnings before interest, taxes, depreciation and amortization (EBITDA) and earnings estimates. Ligand is a biopharmaceutical royalty … Read more

The facts: Cyber insurance for small businesses – Go Health Pro

by
The facts: Cyber insurance for small businesses – Go Health Pro

Cyber insurance for small businesses is probably the furthest thing from your mind. As a small business owner, there’s a lot you have to do to ensure your operation runs smoothly. There’s marketing, ordering products or supplies, customer acquisition, and generally getting work done. But what about cybersecurity?  Are you prepared for cyber risks? Read … Read more

Zacks Small Cap Research – POET: With Cash at $40 Million, POET looks Beyond Providing Samples to Major New Customers and Prepares for Production. – Go Health Pro

by

By Lisa Thompson NASDAQ:POET READ THE FULL POET RESEARCH REPORT POET Inks Deal With Mitsubishi to Design and Market 1.6T and 3.2T Engines Together On Sept. 19th, POET (NASDAQ:POET) announced a deal with Mitsubishi Electric to co-develop integrated optical engine chipsets for 3.2T pluggable transceivers. Mitsubishi Electric will contribute its 400G Electro-absorption Modulator Integrated Lasers … Read more

Zacks Small Cap Research – AI from EVAX Improves Trial Results – Go Health Pro

by

By Brad Sorensen, CFA NASDAQ:EVAX READ THE FULL EVAX RESEARCH REPORT Evaxion (NASDAQ:EVAX) is a clinical stage company that is making AI useful in the current environment by using the technology to develop new cancer-fighting vaccines. The company notes that it has demonstrated that it can identify, through the company’s AI models, novel targets within … Read more

Zacks Small Cap Research – SNGX: Marburg Outbreak Puts Focus on Soligenix Vaccine Development… – Go Health Pro

by
Zacks Small Cap Research – SNGX: Marburg Outbreak Puts Focus on Soligenix Vaccine Development… – Go Health Pro

By David Bautz, PhD NASDAQ:SNGX READ THE FULL SNGX RESEARCH REPORT Business Update Marburg Virus Outbreak Puts Focus on Soligenix Vaccine Development Soligenix, Inc. (NASDAQ:SNGX) is developing vaccines targeting multiple filoviruses, including MarVax, a heat stable vaccine for protection against Marburg virus. Recent events highlight the importance of the company’s vaccine development program. On October … Read more

x